IDH1 and glioblastoma: Twenty-one (91%) tumors had negative SST2A IHC scores; the remaining two high-grade glioma samples received scores of 2 (both glioblastoma, one of which was IDH1-mutant), with interpretation limited somewhat by specimen quality and diffuse non-tumoral, non-membranous background staining (see below) in both cases.